Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.
| Website: | www.corbuspharma.com |
| Email: | ir@corbuspharma.com |
| Main Phone: | +1 617 963-0100 |
| Address: | 500 River Ridge Drive |
| Address 2: | Second Floor |
| State: | MA |
| City / Town: | Norwood |
| Country: | USA |
| Postal Code: | 02062 |
| Exchange: | NSD |
| CEO: | Yuval Cohen |
| Employees: | 77 |
| NAICS: | Biological Product (except Diagnostic) Manufacturing(325414) |
Gathering Data... Please wait Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.
| Website: | www.corbuspharma.com |
| Email: | ir@corbuspharma.com |
| Main Phone: | +1 617 963-0100 |
| Address: | 500 River Ridge Drive |
| Address 2: | Second Floor |
| State: | MA |
| City / Town: | Norwood |
| Country: | USA |
| Postal Code: | 02062 |
| Exchange: | NSD |
| CEO: | Yuval Cohen |
| Employees: | 77 |
| NAICS: | Biological Product (except Diagnostic) Manufacturing(325414) |
| Last Price 7.37 | Change $ 0.29 | Change % 4.10 | Tick N/A |
| Bid 7.20 | Bid Size 3,000.00 | Ask 7.37 | Ask Size 200.00 |
| Open 7.08 | High 7.41 | Low 6.97 | Prev Close 7.08 |
| Last Trade | Volume 851,456 | 52 Wk Hi 9.11 | 52 Wk Low 4.50 |
| Market Cap 475 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 64,455,221.00 | EPS (TTM) -1.21 | PE Ratio N/A | Exchange NSD |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 32 | 32 | 32 | 32 |
| Low Target Price Estimate | 20 | 20 | 20 | 20 |
| Mean Target Price Estimate | 24.67 | 24.67 | 24.67 | 24.67 |
| Standard Deviation | 6.43 | 6.43 | 6.43 | 6.43 |
| Date of Most Recent Estimate | 05/22/18 | 05/22/18 | 05/22/18 | 05/22/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 8-K | Report of unscheduled material events or corporate changes. | 12 | 2018-06-13 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-06 |
| 3 | Initial statement of beneficial ownership of securities | 2 | 2018-06-06 |
| 8-K | Report of unscheduled material events or corporate changes. | 8 | 2018-06-06 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-29 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-29 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-29 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-29 |
| 8-K | Report of unscheduled material events or corporate changes. | 4 | 2018-05-24 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-16 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 |
| Moderate Buy | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.2 | 1.17 | 1.17 | 1.17 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
